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S U M M A R Y
In recent years, carbapenem-resistant Acinetobacter baumannii infections have been responsible for
outbreaks in medical facilities. A 35-year-old Japanese woman developed a skin and soft tissue infection
due to carbapenem-resistant A. baumannii. The isolate was resistant to antibiotics other than ampicillin–
sulbactam and colistin, suggesting drug resistance due to carbapenemase production by OXA-23. We
selected a combination therapy consisting of intravenous ampicillin–sulbactam and meropenem. No
changes were observed in aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, or
serum creatinine during therapy, and carbapenem-resistant A. baumannii was not detected in wound
exudates 3 days after therapy initiation. In our patient’s case, combination therapy with ampicillin–
sulbactam and meropenem was successful. Thus, combination therapy with ampicillin–sulbactam and
meropenem is effective against skin and soft tissue infection due to carbapenem-resistant A. baumannii.
Combination therapy with intravenous ampicillin–sulbactam and meropenem may be an option for skin
and soft tissue infections due to carbapenem-resistant A. baumannii.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Acinetobacter baumannii causes a wide range of nosocomial
infections, including pneumonia, bacteremia, urinary tract infec-
tions, secondary meningitis, and skin and soft tissue infections.
Traditionally, the most effective antimicrobials against A. bau-
mannii have been carbapenems such as imipenem–cilastatin and
meropenem. In recent years, infections due to carbapenem-
resistant A. baumannii have been responsible for frequent out-
breaks in medical facilities.1 Carbapenem resistance is mediated
primarily by carbapenemases, including class D b-lactamases
(OXA-type carbapenemases) and class B metallo-b-lactamases
(MBLs).1 Although the efﬁcacy of a number of antimicrobial
combinations has been demonstrated in vitro, only limited data
support the use of these agents in animal models of carbapenem-
resistant A. baumannii infection. In addition, no randomized
clinical trials have evaluated the optimal antimicrobial regimen
for treating carbapenem-resistant A. baumannii infections. There-
fore, clinicians must use combinations of licensed drugs in the
hope that they will act synergistically.* Corresponding author. Tel.: +81 96 353 6501; fax: +81 96 325 2519.
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carbapenem-resistant A. baumannii infections. Although these
antibiotics act in vitro against many Gram-negative bacilli,
including Acinetobacter spp and Pseudomonas spp, nephrotoxicity
and neurotoxicity are common adverse events.2 Ampicillin–
sulbactam is effective against Acinetobacter spp in vitro, and
combination therapy with this and a carbapenem has been used to
treat carbapenem-resistant A. baumannii infections with some
success.3 However, nearly all of these studies have involved cases
of pneumonia, urinary tract infection, and sepsis; the efﬁcacy of
combination ampicillin–sulbactam therapy for the treatment of
skin and soft tissue carbapenem-resistant A. baumannii infection
remains unclear. The ideal therapeutic approach to A. baumannii
infection should be based on the evaluation of isolate resistance
patterns and clonally related carbapenem resistance. Here, we
report a case of carbapenem-resistant A. baumannii skin infection
successfully treated with a combination of intravenous ampicillin–
sulbactam and meropenem.
2. Case report
A 35-year-old Japanese woman with a history of paranoid
schizophrenia was admitted to our emergency medical care centerses. Published by Elsevier Ltd. All rights reserved.
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methicillin-resistant Staphylococcus aureus (MRSA) was detected
in the wound exudate after endoscopic bone ﬁxation surgery, there
were no symptoms of infection. Vancomycin (20 mg/kg/day) was
administered to prevent MRSA infection. On the third day of
vancomycin treatment, carbapenem-resistant A. baumannii was
isolated from the wound exudate, but MRSA was not found. The
patient’s C-reactive protein (CRP) level was 4.28 mg/dl (normal,
0.2 mg/dl), white blood cell (WBC) count was 11.6  109/l (normal,
3.5–8.5  109/l), blood urea nitrogen (BUN) level was 10 mg/dl
(normal, 8–22 mg/dl), serum creatinine (SCr) level was 0.44 mg/dl
(normal, 0.40–0.70 mg/dl), aspartate aminotransferase (AST) level
was 14 IU/l (normal, 13–33 IU/l), and alanine aminotransferase (ALT)
level was 14 IU/l (normal, 8–42 IU/l). Based on these clinical ﬁndings,
the patient was diagnosed with a skin and soft tissue infection
caused by carbapenem-resistant A. baumannii and administration of
vancomycin was discontinued immediately.
Antimicrobial susceptibility testing revealed resistance to all
examined antibiotics, with the exception of ampicillin–sulbactam
and colistin and, to a lesser extent, minocycline hydrochloride
(Table 1). Combination therapy with ampicillin–sulbactam (ampi-
cillin, 80 mg/kg/day; sulbactam, 40 mg/kg/day) and meropenem
(30 mg/kg/day) was initiated in divided doses three times daily.
Improvements in CRP and WBC count were observed 2 days after
initiating combination therapy. Although carbapenem-resistant A.
baumannii was not detected in wound exudates after 3 days of
therapy, the exudate persisted without improvement. Therefore,
continuous combination therapy with ampicillin–sulbactam and
meropenem was administered to prevent multidrug-resistant
Pseudomonas aeruginosa infection. Occasionally, MRSA was detected
in the wound exudate, but the patient did not develop infectious
disease. No other antibiotics were administered. No changes in AST,
ALT, BUN, or SCr were observed during the prolonged combined
therapy. No adverse events were observed, the wound healed, and
the patient was discharged on day 52 to complete the 45-day course
of combination therapy. One month after discharge, no carbapenem-
resistant A. baumannii was detected in the wound area.
2.1. Mechanisms of antimicrobial drug resistance in A. baumannii
The minimum inhibitory concentration of antibiotics was
determined by the agar dilution method using Clinical and
Laboratory Standards Institute guidelines.4 MBL production was
examined by double-disk synergy test. We also screened theTable 1
Antibiotic susceptibility results for the Acinetobacter baumannii isolatea
Antimicrobial agent MIC (mg/ml) Interpretation
Ampicillin >16 Resistant
Ampicillin–sulbactam <4/6 Susceptible
Piperacillin >64 Resistant
Cefazolin >16 Resistant
Cefepime >16 Resistant
Cefotaxime >32 Resistant
Cefozopran >16 Resistant
Flomoxef >32 Resistant
Amikacin >32 Resistant
Gentamicin >8 Resistant
Minocycline 8 Intermediate
Ciproﬂoxacin >2 Resistant
Levoﬂoxacin >4 Resistant
Meropenem >8 Resistant
Sulfamethoxazole–trimethoprim >40 Resistant
Chloramphenicol >16 Resistant
Colistin 0.5 Susceptible
MIC, minimum inhibitory concentration.
a Susceptibilities were examined by a broth microdilution method, in accordance
with the guidelines of the Clinical and Laboratory Standards Institute.4isolate for OXA-type carbapenemase genes by multiplex PCR.5
MBLs were not produced by the carbapenem-resistant A.
baumannii isolate; however, the isolate harbored the blaOXA-23-
like and intrinsic blaOXA-51-like genes (see Supplementary Material).
Although blaOXA-51-like resistance occurs only after insertion of an
ISAba1 element containing a promoter sequence upstream of the
encoding gene, ISAba1 was not found in the carbapenem-resistant
A. baumannii isolate. These ﬁndings suggest carbapenem resistance
in the isolated carbapenem-resistant A. baumannii strain was at
least partially conferred by blaOXA-23-like carbapenemase.
3. Discussion
In this case of skin and soft tissue infection due to carbapenem-
resistant A. baumannii, we selected combination therapy involving
intravenous ampicillin–sulbactam and meropenem. First, it was
necessary to avoid side effects such as nephrotoxicity and
neurotoxicity; because our patient had a history of paranoid
schizophrenia, side effects would be more difﬁcult to discern in the
presence of subjective and objective symptoms. In a large
retrospective study of patients with A. baumannii infection
conducted over an 8-year period, better outcomes were obtained
with ampicillin–sulbactam than with polymyxin.3 Betrosian et al.
also reported that, in comparison to the results obtained for
colistin used at 3 million units three times daily, high doses of
ampicillin–sulbactam exhibited a similar safety and efﬁcacy
proﬁle in critically ill patients with A. baumannii pneumonia.2 In
a retrospective study of patients with carbapenem-resistant A.
baumannii bacteremia, the combination of a carbapenem and
ampicillin–sulbactam was found to be associated with superior
outcomes in comparison to those obtained with carbapenem plus
amikacin or carbapenem alone.
Ampicillin–sulbactam is available in a number of countries and
may be a suitable option for treating infections caused by
Acinetobacter spp. The in vitro activity of sulbactam against clinical
carbapenem-resistant A. baumannii strains ranges from 30% to
45%.1 These reports demonstrate the efﬁcacy of ampicillin–
sulbactam monotherapy for treating serious A. baumannii infec-
tions and suggest that sulbactam would be suitable for combina-
tion therapy with other antibiotics.3 A. baumannii outbreaks
worldwide are caused by a limited number of genotypic clusters of
multidrug-resistant strains. A. baumannii strains carrying the
blaOXA-23-like carbapenemase gene are among the most prevalent
carbapenem-resistant Acinetobacter species in Asian countries. In
this case, we found that the carbapenem resistance of the clinical A.
baumannii isolate was conferred by the blaOXA-23-like carbapene-
mase (see Supplementary Material). Therefore, routine use of
combined ampicillin–sulbactam and carbapenem therapy may be
effective in the treatment of infectious disease due to the most
prevalent carbapenem-resistant A. baumannii strains that produce
blaOXA-23-like carbapenemase.
In conclusion, combination therapy with intravenous ampicil-
lin–sulbactam and meropenem resulted in both clinical and
microbiological cure without signiﬁcant acute complications or
adverse effects. To our knowledge, this is the ﬁrst report of the
successful treatment of a complicated skin and soft tissue infection
due to carbapenem-resistant A. baumannii using intravenous
ampicillin–sulbactam and meropenem. As the frequency of
secondary infections caused by multidrug-resistant organisms
such as A. baumannii continues to rise, more data on the efﬁcacy of
combination therapies such as ampicillin–sulbactam and mer-
openem will be necessary to develop effective treatment regimens
for carbapenem-resistant A. baumannii infection.
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